Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway

Biochemical Pharmacology

Volumn 96, Issue 3, 2015, Pages 278-287

  Giurdanella, Giovanni ^a   Anfuso, Carmelina Daniela ^a   Olivieri, Melania ^a   Lupo, Gabriella ^a   Caporarello, Nunzia ^a   Eandi, Chiara M ^b,c   Drago, Filippo ^a   Bucolo, Claudio ^a   Salomone, Salvatore ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b INSTITUT DE LA VISION   (France)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Aflibercept; Bevacizumab; Diabetic retinopathy; Ranibizumab; VEGF

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CYCLOOXYGENASE 2; CYTOSOLIC PHOSPHOLIPASE A2; GLUCOSE; LACTATE DEHYDROGENASE; MESSENGER RNA; PROSTAGLANDIN E2; RANIBIZUMAB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; ARACHIDONIC ACID DERIVATIVE; ARACHIDONYLTRIFLUOROMETHANE; ENZYME INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; PHOSPHOLIPASE A2; PTGS2 PROTEIN, HUMAN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; MTT ASSAY; PERICYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETINA CELL; ANTAGONISTS AND INHIBITORS; CELL COUNT; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHOSPHORYLATION; PRIMARY CELL CULTURE; RETINA; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ARACHIDONIC ACIDS; CELL COUNT; CELL SURVIVAL; CYCLOOXYGENASE 2; ENZYME INHIBITORS; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; PERICYTES; PHOSPHOLIPASES A2; PHOSPHORYLATION; PRIMARY CELL CULTURE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84934866103     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2015.05.017     Document Type: Article

References (35)

1. D.R. Matthews, I.M. Stratton, S.J. Aldington, R.R. Holman, and E.M. Kohner Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69 Arch. Ophthalmol. 122 2004 1631 1640
2. R. Klein, B.E. Klein, S.E. Moss, M.D. Davis, and D.L. DeMets The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema Ophthalmology 91 1984 1464 1474
3. L.M. Aiello Perspectives on diabetic retinopathy Am. J. Ophthalmol. 136 2003 122 135
4. G. Virgili, M. Parravano, F. Menchini, and J.R. Evans Anti-vascular endothelial growth factor for diabetic macular oedema Cochrane Database Syst. Rev. 10 2014 CD007419
5. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group Ophthalmology 98 1991 807 822
6. J.M. Tarr, K. Kaul, M. Chopra, E.M. Kohner, and R. Chibber Pathophysiology of diabetic retinopathy ISRN Ophthalmol. 2013 2013 343560
7. C.N. Valdez, J.F. Arboleda-Velasquez, D.S. Amarnani, L.A. Kim, and P.A. D'Amore Retinal microangiopathy in a mouse model of inducible mural cell loss Am. J. Pathol. 184 2014 2618 2626
8. E. Beltramo, and M. Porta Pericyte loss in diabetic retinopathy: mechanisms and consequences Curr. Med. Chem. 20 2013 3218 3225
9. J.W. Miller, J. Le Couter, E.C. Strauss, and N. Ferrara Vascular endothelial growth factor a in intraocular vascular disease Ophthalmology 120 2013 106 114
10. M. Shibuya Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases J. Biochem. 153 2013 13 19
11. T. Qaum, Q. Xu, A.M. Joussen, M.W. Clemens, W. Qin, and K. Miyamoto VEGF-initiated blood-retinal barrier breakdown in early diabetes Invest. Ophthalmol. Vis. Sci. 42 2001 2408 2413
12. L.P. Aiello, R.L. Avery, P.G. Arrigg, B.A. Keyt, H.D. Jampel, and S.T. Shah Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N. Engl. J. Med. 331 1994 1480 1487
13. J.I. Greenberg, D.J. Shields, S.G. Barillas, L.M. Acevedo, E. Murphy, and J. Huang A role for VEGF as a negative regulator of pericyte function and vessel maturation Nature 456 2008 809 813
14. E.A. Pierce, R.L. Avery, E.D. Foley, L.P. Aiello, and L.E. Smith Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization Proc. Natl. Acad. Sci. U.S.A. 92 1995 905 909
15. M. Salmeri, C. Motta, C.D. Anfuso, A. Amodeo, M. Scalia, and M.A. Toscano VEGF receptor-1 involvement in pericyte loss induced by Escherichia coli in an in vitro model of blood brain barrier Cell Microbiol. 15 2013 1367 1384
16. R. Cao, Y. Xue, E.M. Hedlund, Z. Zhong, K. Tritsaris, and B. Tondelli VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy Proc. Natl. Acad. Sci. U.S.A. 107 2010 856 861
17. G. Giurdanella, C. Motta, S. Muriana, V. Arena, C.D. Anfuso, and G. Lupo Cytosolic and calcium-independent phospholipase A(2) mediate glioma-enhanced proangiogenic activity of brain endothelial cells Microvasc. Res. 81 2011 1 17
18. G. Lupo, C. Motta, G. Giurdanella, C.D. Anfuso, M. Alberghina, and F. Drago Role of phospholipases A2 in diabetic retinopathy: in vitro and in vivo studies Biochem. Pharmacol. 86 2013 1603 1613
19. G. Lupo, C. Motta, M. Salmeri, V. Spina-Purrello, M. Alberghina, and C.D. Anfuso An in vitro retinoblastoma human triple culture model of angiogenesis: a modulatory effect of TGF-beta Cancer Lett. 354 2014 181 188
20. F. Sennlaub, F. Valamanesh, A. Vazquez-Tello, A.M. El-Asrar, D. Checchin, and S. Brault Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy Circulation 108 2003 198 204
21. Q. Zhang, D. Wang, N.K. Singh, V. Kundumani-Sridharan, L. Gadiparthi, and M. Rao Ch Activation of cytosolic phospholipase A2 downstream of the Src-phospholipase D1 (PLD1)-protein kinase C gamma (PKCgamma) signaling axis is required for hypoxia-induced pathological retinal angiogenesis J. Biol. Chem. 286 2011 22489 22498
22. R. Pai, I.L. Szabo, B.A. Soreghan, S. Atay, H. Kawanaka, and A.S. Tarnawski PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways Biochem. Biophys. Res. Commun. 286 2001 923 928
23. G. Lupo, A. Nicotra, G. Giurdanella, C.D. Anfuso, L. Romeo, and G. Biondi Activation of phospholipase A(2) and MAP kinases by oxidized low-density lipoproteins in immortalized GP8.39 endothelial cells Biochim. Biophys. Acta 1735 2005 135 150
24. C.D. Anfuso, G. Lupo, L. Romeo, G. Giurdanella, C. Motta, and A. Pascale Endothelial cell-pericyte cocultures induce PLA2 protein expression through activation of PKCalpha and the MAPK/ERK cascade J. Lipid Res. 48 2007 782 793
25. J.F. Arevalo, R.A. Garcia-Amaris, J.A. Roca, J.G. Sanchez, L. Wu, and M.H. Berrocal Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group J. Cataract Refract. Surg. 33 2007 2098 2105
26. H. Zong, M. Ward, A. Madden, P.H. Yong, G.A. Limb, and T.M. Curtis Hyperglycaemia-induced pro-inflammatory responses by retinal Muller glia are regulated by the receptor for advanced glycation end-products (RAGE) Diabetologia 53 2010 2656 2666
27. M.B. Manigrasso, J. Juranek, R. Ramasamy, and A.M. Schmidt Unlocking the biology of RAGE in diabetic microvascular complications Trends Endocrinol. Metab. 25 2014 15 22
28. A. Bierhaus, S. Schiekofer, M. Schwaninger, M. Andrassy, P.M. Humpert, and J. Chen Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB Diabetes 50 2001 2792 2808
29. L.K. Nguyen, M.A. Cavadas, B.N. Kholodenko, T.D. Frank, and A. Cheong Species differential regulation of COX2 can be described by an NFkappaB-dependent logic AND gate Cell. Mol. Life Sci. 2015
30. T. Hirabayashi, T. Murayama, and T. Shimizu Regulatory mechanism and physiological role of cytosolic phospholipase A2 Biol. Pharm. Bull. 27 2004 1168 1173
31. K. Ishihara, K. Tsutsumi, S. Kawane, M. Nakajima, and T. Kasaoka The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site FEBS Lett. 550 2003 107 113
32. S.H. Chang, C.H. Liu, R. Conway, D.K. Han, K. Nithipatikom, and O.C. Trifan Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression Proc. Natl. Acad. Sci. U.S.A. 101 2004 591 596
33. E.C. Jaeckel, S. Raja, J. Tan, S.K. Das, S.K. Dey, and D.A. Girod Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma Arch. Otolaryngol. Head Neck Surg. 127 2001 1253 1259
34. M. Franco, P. Roswall, E. Cortez, D. Hanahan, and K. Pietras Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression Blood 118 2011 2906 2917
35. N.K. Singh, D.E. Hansen 3rd, V. Kundumani-Sridharan, and G.N. Rao Both Kdr and Flt1 play a vital role in hypoxia-induced Src-PLD1-PKCgamma-cPLA(2) activation and retinal neovascularization Blood 121 2013 1911 1923